Literature DB >> 8784355

Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme.

A Desmyter1, T R Transue, M A Ghahroudi, M H Thi, F Poortmans, R Hamers, S Muyldermans, L Wyns.   

Abstract

The Camelidae is the only taxonomic family known to possess functional heavy-chain antibodies, lacking light chains. We report here the 2.5 A resolution crystal structure of a camel VH in complex with its antigen, lysozyme. Compared to human and mouse VH domains, there are no major backbone rearrangements in the VH framework. However, the architecture of the region of VH that interacts with a VL in a conventional FV is different from any previously seen. Moreover, the CDR1 region, although in sequence homologous to human CDR1, deviates fundamentally from the canonical structure. Additionally, one half of the CDR3 contacts the VH region which in conventional immunoglobulins interacts with a VL whereas the other half protrudes from the antigen binding site and penetrates deeply into the active site of lysozyme.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784355     DOI: 10.1038/nsb0996-803

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  128 in total

1.  Single-domain antibody fragments with high conformational stability.

Authors:  Mireille Dumoulin; Katja Conrath; Annemie Van Meirhaeghe; Filip Meersman; Karel Heremans; Leon G J Frenken; Serge Muyldermans; Lode Wyns; Andre Matagne
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

2.  Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells.

Authors:  Viet Khong Nguyen; Xiangang Zou; Marc Lauwereys; Lea Brys; Marianne Brüggemann; Serge Muyldermans
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

3.  Structural modeling extends QSAR analysis of antibody-lysozyme interactions to 3D-QSAR.

Authors:  Eva K Freyhult; Karl Andersson; Mats G Gustafsson
Journal:  Biophys J       Date:  2003-04       Impact factor: 4.033

4.  Contributions of conventional and heavy-chain IgG to immunity in fetal, neonatal, and adult alpacas.

Authors:  L P Daley-Bauer; S R Purdy; M C Smith; L F Gagliardo; W C Davis; J A Appleton
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

5.  Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor.

Authors:  V A Streltsov; J N Varghese; J A Carmichael; R A Irving; P J Hudson; S D Nuttall
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-10       Impact factor: 11.205

6.  Dual beneficial effect of interloop disulfide bond for single domain antibody fragments.

Authors:  Jochen Govaert; Mireille Pellis; Nick Deschacht; Cécile Vincke; Katja Conrath; Serge Muyldermans; Dirk Saerens
Journal:  J Biol Chem       Date:  2011-11-29       Impact factor: 5.157

7.  Molecular imprint of enzyme active site by camel nanobodies: rapid and efficient approach to produce abzymes with alliinase activity.

Authors:  Jiang-Wei Li; Lijie Xia; Youhong Su; Hongchun Liu; Xueqing Xia; Qinxia Lu; Chunjin Yang; Kalbinur Reheman
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

8.  Comparison of fusion phage libraries displaying VH or single-chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules.

Authors:  X Cai; A Garen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 9.  Nanobodies as Probes for Protein Dynamics in Vitro and in Cells.

Authors:  Oleg Y Dmitriev; Svetlana Lutsenko; Serge Muyldermans
Journal:  J Biol Chem       Date:  2015-12-16       Impact factor: 5.157

10.  Structure and binding properties of a cameloid nanobody raised against KDM5B.

Authors:  Anders Wiuf; Line Hyltoft Kristensen; Ole Kristensen; Jerzy Dorosz; Jonas Jensen; Michael Gajhede
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-09-23       Impact factor: 1.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.